Therapeutics for Inpatients with COVID-19 (TICO)/ACTIV-3 - Clinical Trial

What is the Purpose of this Study?

This research study is looking at a new investigational drugs to see if they can help people with COVID-19 get better and go home faster.

What is the Condition Being Studied?

COVID-19

Who Can Participate in the Study?

Adults who have tested positive for COVID-19 within the last 3 days and need to be admitted to the hospital.

Age Group
Adults

What is Involved?

If you agree to be in this study, you will:
-Be randomly assigned to 1 of 4 groups
---Groups 1, 2, and 3 will get a dose of a study drug through a vein in your arm (This means you have 3 out of 4 possibility to get a study drug)
---Group 4 will get a placebo (harmless saline with no medicine) through a vein in your arm

-Both groups will:
-Get Remdesivir (an antiviral medication being used to treat COVID-19)
-Have a nasal swab collected
-Have blood samples taken up to 5 times in the first 3 months of the study.
-Allow the study team to review your medical information for up to 1 year after the study is finished

Study Details

Full Title
A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients with COVID-19
Principal Investigator
Heart Surgeon
Protocol Number
IRB: PRO00106339
Phase
Phase III
Enrollment Status
Open for Enrollment
Participate
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698